Navigation Links
Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
Date:12/8/2010

CULVER CITY, Calif., Dec. 8, 2010 /PRNewswire/ -- Sofie Biosciences, a developer of agents and devices for the molecular imaging of disease, announced today the closing of an additional $2 million from new and existing investors. Funds will be used for the development of new PET imaging agents and for enhancements to their PET imaging systems and chemistry units. The round includes the first institutional and large corporate financing to the firm including investment by the Cycad Group.

(Logo: http://photos.prnewswire.com/prnh/20101208/LA13841LOGO)

"This investment represents an important step towards achieving our goal of rapidly commercializing new PET technologies and imaging agents in an effort to make PET more widely accessible to more physicians and scientists," said Patrick Phelps, President and CEO of Sofie.

Sofie Biosciences is developing novel molecular imaging agents to enable earlier and more accurate diagnosis, treatment selection, and therapeutic monitoring of major medical disorders. Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease.

Sofie's founders are leading scientists and clinicians in the field. They include the inventor of the PET scanner and Chairman of the Department of Molecular & Medical Pharmacology at UCLA, Dr. Michael Phelps; the Director of The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, Dr. Owen Witte; the Director of The Ahmanson Biological Imaging Division at UCLA, Dr. Johannes Czernin; and the Director of the NCI Nanosystems Cancer Center at Caltech, Dr. James Heath.

Sofie has obtained an exclusive license from the University of California to a family of PET molecular imaging agents collectively referred to as FAC. FAC has been shown in preclinical animal research a
'/>"/>

SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  AVACEN, Inc. announced today the issue by the ... medical technology platform supporting its unique Dry Heat Therapy AVACEN ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal ... methods of use, referred to by the company as the ...
(Date:7/1/2015)... 1, 2015 Radiant Insights announce ... Oxygen Concentrators Market Shares, Strategy, and Forecasts, Worldwide, ... continuing growth as the aging population worldwide needs homecare ... conditions where oxygen is able to improve the quality ... have become affordable and support a mobile lifestyle even ...
(Date:7/1/2015)... , July 1, 2015 ... is expected to reach USD 49,119.2 million by 2020, ... Inc. Monitoring services is expected to remain the dominant ... USD 1,227.5 million in 2012, and an estimated CAGR ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse full ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... following statement,by Andrea Kavanagh, Director of the Pure Salmon ... publish a study tomorrow that,shows sea lice from open ... wild fish stocks., "This study confirms what we ... havoc on wild salmon populations. If outbreaks of these,parasites ...
... Results, SOUTH SAN FRANCICSO, Calif., Dec. 13 ... announced that its oral syk,kinase inhibitor, R788 (tamatinib ... Arthritis (RA) patients in a,recently completed Phase 2 ... 150mg po bid (orally, twice daily), showed higher ...
Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion Bootie, ... Customers purchasing two or more Bunion Booties directly from their website, ... Bootie temporarily corrects misaligned toes and its ultra thin properties allow for protection ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the only full-service leadership ... chief nursing officer recruitment for Capital Health in Pennington, N.J. ... E. Smith has recently placed more than 1,000 healthcare executives into organizations. , ...
(Date:7/1/2015)... ... ... Who doesn’t want a life filled with thriving positivity and high-life satisfaction? ... and life, and positive friendships and relationships? , Dr. Marsha W. Snyder explains ... Doctors. , With a focus on solving the epidemic of ill-being in the medical ...
(Date:7/1/2015)... ... July 01, 2015 , ... METTLER TOLEDO is ... larger-than-average weighing pans, ML-T balances give operators the room they need to carry ... real estate makes ML-T balances a perfect choice for day-to-day weighing in nearly ...
(Date:7/1/2015)... ... ... The executive team from Nutritional Products International, a ... and beauty products, announced the company was successful in forging some important new ... in Tampa, Florida. This specific ECRM trade show gives companies in the nutritional, ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Medical Doctor Explains The Healthy Effects of a Positive Outlook in New Book 2Health News:METTLER TOLEDO Launches Compact ML-T Balances: Larger Pan Offers Greater Weighing Flexibility in Tight Spaces 2Health News:NPI Executives Report Great Success at ECRM Conference 2
... University of Alabama at Birmingham (UAB) have been selected ... project is a national consortium of cutting-edge hospitals and ... patients with a kind of malignant brain tumor called ... UAB will serve as the only research site in ...
... Colo., July 9 If your eye ... inside!, would you use it? Probably not. ... commonly-used chemicals Dimethicone,Glyceryl Sterate, DMDM Hydantoin and ... and skin irritating emulsifiers and,preservatives., Most ...
... GCI Health meets global needs for the increasingly complex healthcare ... ... 9 Cohn & Wolfe has announced the,formation of GCI Health, ... the healthcare industry. GCI Health, which,will be led by Jill Dosik ...
... vote soon on legislation that would cut $39 ... July 9 Seniors across,Mississippi are speaking out ... legislation being considered in the U.S. Senate. The,legislation ... Medicare Advantage,program in Mississippi alone and severely cut ...
... Governor Edward G.,Rendell today signed House Bill 1150 ... protections for children and young,adults with Autism Spectrum ... medically necessary treatments,for individuals with autism up to ... essential services and treatments by building a stronger ...
... MONICA, Calif., July 9 Cord Blood,America, ... cord blood stem,cell preservation company ( http://www.cordblood-america.com ... of stem cells to families nationwide and,internationally, ... interviewed,about the Company,s achievements and future strategies ...
Cached Medicine News:Health News:UAB joins elite brain cancer research group 2Health News:Clean, Chemical-Free Eye Cream Evening Primrose Oil: The Puffy-Eye Cure 2Health News:Cohn & Wolfe Launches GCI Health, One of the World's Largest Healthcare Public Relations Firms 2Health News:Mississippi Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Pennsylvania Governor Rendell Signs Bill Ensuring Continuity of Care for Children, Young Adults with Autism 2Health News:Cord Blood America CEO Matthew Schissler Details Aggressive Expansion Strategies in U.S. and Europe 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: